Different laboratories reported contradictory results regarding the involvement of the individual activating FcγRs using one of the three B16-F10 tumor model variants and different panels of FcγR deficient mice and FcγR blocking antibodies [13, 14, 17–19]. The gene discussed is FCGR2A; the disease is neoplasm.